IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid

James, T., Salman, S., Stevenson, B., Bundell, C., Kelly, G., Nolan, D. and John, M. (2019) IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clinical Immunology, 198 . pp. 54-56.

Abstract

Bullous pemphigoid (BP) is a blistering dermopathy and a prototypic antibody-mediated autoimmune disease. Detection of IgG autoantibodies against hemidesmosomal proteins BP180 and/or BP230 are diagnostic and levels can correlate with disease activity. Therapies include corticosteroids and oral immunosuppressants, while intravenous immunoglobulin and rituximab are reserved for treatment resistant cases. Here we describe a patient with severe BP which was refractory to standard first line therapy, intravenous immunoglobulin and rituximab induced depletion of peripheral B cells. Use of the monoclonal anti-IgE antibody omalizumab resulted in rapid resolution of blistering despite ongoing high levels of anti-skin IgG antibodies. To our knowledge this is the first case of BP responsive to omalizumab after failure of rituximab to be reported. This case adds to emerging data on omalizumab as a novel BP treatment as well as providing new evidence of an independent role for autoreactive IgE-mediated inflammation in the formation of BP skin lesions.

Item Type:	Journal Article
Murdoch Affiliation(s):	Institute for Immunology and Infectious Diseases
Publisher:	Academic Press Inc.
Copyright:	© 2018 Published by Elsevier Inc
URI:	http://researchrepository.murdoch.edu.au/id/eprint/42955

Item Control Page